believ rct failur put payor
coverag genesight risk
case miss industri expert confer call et friday
listen replay follow public genesight guid studi
host engag discuss lead academ psychiatrist dr charl
nemeroff includ myriad evp clinic dev dr bryan
dechairo dr nemeroff import thought leader chair task forc
novel biomark treatment issu neg guidelin statement
pharmacogenet genesight juli dr nemeroff view ultim gospel
genesight come payor coverag keeper key
guidelin guid studi summarili note studi fail
also reiter group juli guidelin statement offici view
would chang follow guid public simpli put
without guidelin support see path coverag expans genesight
share concern genesight rct failur remain concern
potenti non-coverag test medicar updat sensit
analysi follow guid public lower pt
tool time confer call takeaway highlight call
myriad dr bryan dechairo ask first question defend
guid result debat dr nemeroff opinion dr nemeroff soundli
debat guid dr nemeroff view fail studi dr nemeroff
also clear task forc neg guidelin statement offici
guidelin posit dr nemeroff also believ fda statement
mirror apa statement appli genesight even referenc pleas
listen replay call dial-in passcod
new observ guid myriad fail primari endpoint four nine
secondari endpoint publish total congruenc analysi show
genesight potenti help subset popul
public timelin inconsist myriad public commentari
studi author employ directli myriad includ senior author
anoth research consult affili assurex subsidiari
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
underweight believ sever risk
discount share unfavor
risk/reward notabl see sever risk around
genesight rct impact studi present
risk payor coverag addit cautiou
around hct price see risk counsyl move
out-of-network note outstand
upsid case reflect normal
ebitda multipl upsid ebitda forecast
upsid ebitda forecast assum
genesight doubl reimburs coverag
cover live compar ebitda
downsid case reflect normal
ebitda multipl downsid ebitda
forecast downsid ebitda forecast
assum genesight earn non-coverag
decis myriad reduc salesforc
help off-set cost headwind
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
action reiter underweight lower price target
myriad genet thesi pleas
non-coverag repres myriad ultim downsid
tool time expert call dr charl nemeroff
guid dr nemeroff view fail studi
dr nemeroff vs myriad dr dechairo debat heard across diagnost
commun wall street
dr nemeroff task forc neg guidelin statement
dr nemeroff also believ fda statement mirror apa
statement appli genesight even referenc
new observ guid studi
action reiter underweight lower price target
maintain underweight rate lower price target
given review guid studi top industri expert field
clear genesight guidelin support without guidelin support
myriad simpli earn broader reimburs coverag test chart
includ scenario analysi myriad valuat vari level genesight
reimburs coverag given test asp everi chang coverag
add asp toggl financi contribut genesight
determin payor coverag impact revenu earn assum flow-
new revenu ebitda keep volum static forecast
test weight averag outcom drive price target myriad
base myriad current coverag medicar carefirst togeth
code stack non-cov live myriad current gener revenu around
list price normal ev/ebitda multipl
entir busi impli myriad valu around per share current genesight
coverag share trade impli myriad coverag
expand patient popul
downsid describ think unlik myriad earn
broader coverag ultim downsid case would medicar issu non-
coverag determin genesight rais probabl
follow review guid studi dr nemeroff medicar
non-coverag determin would drive genesight neg ebitda contributor
base convers myriad believ non-coverag scenario
compani would absorb loss keep product market addit
cost per test variabl around per test myriad current employ
salesforc around individu scenario analysi assum
salesforc reduct increas coverag reduc around per test
essenti code-stack reimburs myriad could earn non-cov test
also assum myriad pursu addit cost reduct measur
though action wont fulli off-set dilut impact medicar non-coverag
downsid case repres downsid ebitda million
upsid could alway wrong myriad would argu earn
coverag decis carefirst april could signal futur opportun
ahead said believ potenti limit given think singl
exampl test guidelin support earn payor coverag
case genesight neg guidelin statement activ refut valu
test upsid case repres upsid ebitda million
downsid case may seem overli punit believ scenario
investor prepar cope genesight non-cov genesight
non-cov myriad consist hereditari cancer test busi estim
gener ebitda declin per year well
number product contribut neg ebitda non-coverag scenario
limit visibl product could contribut posit
thesi addit would real strateg concern myriad genesight
non-coverag scenario effort diversifi crescendo sividon assurex
non-coverag scenario would pan counsyl alreadi show sign
weak out-of-network decis given myriad signific
remain concentr hereditari cancer test structur price risk
would appli discount multipl nation lab asset note
labcorp quest trade ebitda given overhang two
hhs/oig investig well outstand materi weak intern control
view risk myriad acquir unlik downsid scenario includ
potenti penalti could levi part investig
sensit analysi genesight price drive new price
myriad genet thesi pleas
downgrad myriad genet underweight page
report dx industri updat select view sentiment surpass market risk
myriad genet new concern impact pt
uw pt
industri earn preview myriad genet thought page
preview reset expect put focu solid fundament
tool kit volume issu view competit environ
thought
wait continu genesight rct public barclay
genesight later fda warn pharmacogenet
myriad genet question new genesight risk emerg lower
pt
guid accept public set motion rct catalyst
pleas see myriad section outlook outlook tool
tool kit volume issu genesight takeaway journal
genesight rev vari ebitda vari reduct per rep save forecast forecast myriad multipl stock price target weight stock price current coverageupsid myriaddownsid non-coveragemyriad genet valuat analysi sensit genesight barclay
pleas see report
updat select view
pleas see report
genet thought
non-coverag repres myriad
believ possibl could re-review genesight clinic literatur
also critic guid impact optum studi genesight
test complet myriad collect million revenu major
believ medicar medicaid program believ four potenti
catalyst re-review genesight dossier materi clinic updat
genesight rct impact optum studi rais attent
point myriad activ discuss medicar result studi
effort expand order label primari care physician full literatur
review would rais question around current coverag psychiatrist discuss
downgrad report academ literatur recent publish
seem refut qualiti data use issu lcd given
signific cost medicar could undergo review part nation coverag
current stand believ ground current genesight coverag remain
weak base coverag analysi qualiti strength evid
list moder genesight weight evid list limit
excerpt genesight local coverag decis lcd
interestingli five studi cite evid medicar lcd
critiqu dr nemeroff american journal psychiatri ajp academ public
hamm la cross studi problemat due lack blind
import protocol psychiatr trial given mental disord
potenti placebo effect materi impact studi result
signific pine rest studi address issu blind studi
small sampl size miss sever clinic endpoint
critiqu literatur use coverag decis
pleas see studi
activ score rheumatoid
abatacept adalimumab
multipl preced review new clinic literatur
issu non-coverag decis specialti diagnost myriad vectra da opko
cover test previous receiv draft non-coverag decis
medicar base new clinic data view believ non-coverag
decis would detriment genesight medicar primari payor current
without medicar coverag myriad would limit volum cut cost addit
believ would difficult obtain increment commerci coverag without
discuss histor preced non-coverag decis
non-coverag decis vectra da base studi publish august
evalu test result specif interv studi object
studypatientsresultspushbackclinicalhamm studyprospect nonrandom open-label cohort-compar studi assess clinic util genesight report genesight-guid cohort versu treatment-as-usu tau statist signific reduct qids-c blind -small sampl size -short durat studi la crosselarg replic studi studi assess reduct symptom genesight-guid cohort versu tau signific result respect symptom improv respons remiss -genesight alter medic baselin result higher percentag patient take congruent medication-lack blind -statist signific differ treatment group symptom sever treatment resist metabol phenotyp distribut baselinepin restdouble-blind random control trial assess reduct symptom genesight-guid cohort versu tau show statist signific respect symptom improv respons remiss -patient genesight-guid arm like congruent medic week -studi miss symptom improv respons remiss endpoint -small sampl size meta-analysi studya meta-analysi conduct increas statist power two open-label one random studi abovecombin three studi test associ increas odd patient achiev respons remiss signific reduct score -genesight-guid treatment benefici patient red bucket -lack blind two three studieseconomicdayton studya one-year blind retrospect studi determin cost-effect cost save associ red bin green bin -in compar patient red green bin number outpati healthcar visit number medic absenc day number disabl claim significantli greater red bin -total annual cost save amount -sever healthcar util measur meet statist significance-sever measur meet signific includ inpati visit -inclus patient anxieti disord -lack tau groupcompanyopkomyriad solut medicar administr contractor cover bio-refer diagnost segment opko elmwood park nj laboratori issu non-coverag decis compani test review non-coverag decis believ similar sever critic heard genesight test first non-coverag decis cite test undergon fda review scrutini similar genesight second report note data suggest one four biomark littl clinic signific three biomark type test done commerci lower cost relat genesight without abl understand myriad algorithm dont know valu individu gene similar test genesight includ gene commerci avail stand-alone test cheaper cost genesight compar assay third decis highlight valid patient outsid intend use popul issu non-coverag decis myriad vectra da later revers said believ origin action issu non-coverag decis provid us insight agenc think issu coverag updat non-coverag decis issu result studi publish journal american colleg rheumatolog august studi found result vectra da inconsist measur rheumatoid arthriti ra diseas activ methodolog use come find later refut myriad research univers alabama non-coverag decis issu approxim four month public decemb believ prove could make decis rel short period time addit roughli million revenu larg coverag limit medicar vectra da repres signific cost medicar barclay
assess vectra da abil reflect clinic measur diseas activ patient enrol
ampl trial support bristol-my squibb ampl trial patient
activ ra nave biolog agent inadequ respons
methotrex random receiv subcutan abatacept mg everi week
subcutan adalimumab mg everi week background methotrex
year vectra da use evalu diseas activ baselin month year
mean chang baselin compar amongst two treatment group
vectra da compar four clinic measur diseas activ clinic
score joint use c-reactiv protein level routin assess
patient index data research conclud associ
vectra da score diseas activ defin measur
specif concern statist signific discord
vectra da score chang month year across two patient group
abatacept adalimumab despit similar clinic efficaci
non-coverag commentari local coverag determin lcd vectra da mbda test
tool time expert call dr charl nemeroff
case miss industri expert confer call et friday
listen replay follow public genesight guid studi host
engag discuss lead academ psychiatrist dr charl nemeroff
includ myriad evp clinic develop dr bryan dechairo dr
nemeroff import thought leader chair task forc novel
biomark treatment
issu neg guidelin statement
pharmacogenet genesight juli dr nemeroff view ultim gospel
genesight come payor coverag keeper key guidelin
recommend guid studi summarili note studi fail
also reiter group juli guidelin statement offici view
would chang follow guid public simpli put without
guidelin support see path coverag expans genesight share
concern genesight rct failur remain concern potenti non-
coverag test medicar updat sensit analysi follow
guid public lower pt
background consid dr charl nemeroff one top industri expert
pharmacogenet treatment resist depress notabl dr charl nemeroff led
task forc novel biomark treatment compon council
research review pharmacogenet test juli dr nemeroff
group determin gene test antidepress efficaci conclud test yet
readi widespread use dr nemeroff also lead author studi publish
american journal psychiatri april clinic implement
pharmacogenet decis support tool antidepress drug prescrib
pleas listen replay call dial-in passcod
guid dr nemeroff view fail studi
dr nemeroff view guid data clear fail studi critic
result given primari endpoint fail primari outcom measur
realiz secondari data analysi realli isnt valid fail
primari endpoint unfortun data live
discuss rct primari outcom failur implic guid studi
 let start hope could give us high level thought guid studi
publish morn interpret result
 dr nemeroff posit side certainli largest studi commerci provid
pharmacogenom test conduct certainli congratul also say
fair whenev read us read studi alway easi retrospect critic true studi well
everybodi els abl say well probabl done way done way etc
said salient import find studi fact fail studi
hypothesi primari hypothesi test studi pharmacogenom test would
impact clinic outcom primari outcom measur fail show differ us
import find primari outcom measur hamilton depress rate scale see
result section well figur tabl result signific actual even
close signific
terribl sophist area statist analysi scientif evidence-bas medicin
extraordinarili import observ decreas primari endpoint score
genom guid arm compar treatment usual anywher close
statist signific reason import anyon taken statist cours know
primari outcom measur realiz secondari data analysi realli isnt valid
interest mayb interest well talk term subsequ studi might perform
absenc primari outcom measur signific say interest im
sure well talk secondari outcom measur
jargon psychiatr clinic trial simpli fail trial fail show differ primari
outcom measur unlik look treatment trial compar drug placebo fda look new
drug compar placebo primari outcom measur met never approv fda regardless
secondari outcom measur might show think first take home messag unfortun
data live
dr nemeroff vs myriad dr dechairo debat heard across
diagnost commun wall street
highlight call myriad evp clinic develop dr bryan
dechairo ask first question defend guid result
debat dr nemeroff whole exchang worth read first dr dechairo
question dr nemeroff view guid remiss rate unusu low
compar result prior studi dr nemeroff note
statist power behind remiss rate patient fail multipl
therapi sinc infinitesim small number patient reach
medic threshold dechairo note studi show statist
signific improv side effect subset patient start genet
inappropri therapi dr nemeroff proceed read dechairo studi
note statist signific differ guid care arm
treatment usual regard number mean side effect week
proport patient experienc side effect differ final
dechairo argu preced studi fail primari endpoint
still consid success compar prozac fda approv dr nemeroff
alert dechairo bring except would happen
today opinion dr nemeroff soundli debat
 debat myriad genet dr charl nemeroff
 oper first come line scott gleason
 dr bryan dechairo hi bryan dechairo im execut vice presid clinic develop myriad
also senior author guid studi thank dr nemeroff thought public today one
clarifi statement two quick question dont mind
first clarifi side effect see patient public statist signific impact
patient genet inappropri medic genesight switch versu
stay signific side effect well symptom improv respons remiss
group patient would benefit pharmacogenom test
two question regard statement remiss primari endpoint symptom improv
well first would like get thought data brought guid studi patient
enrol state fail least medic averag patient fail around medic
would like get thought saw remiss rate around patient
third fourth round fail medic similar averag number failur
guid studi wonder felt data remiss rate would typic would
expect see guid also seen impact studi
 dr nemeroff let answer one first first patient refer fail mani
trial small number extrem small statist power term number quot
patient trial infinitesim small number patient reach
threshold look data patient higher remiss rate quot
think particularli hold water
want make one comment question address side effect pharmacogenom
arm actual show fewer side effect treatment usual group
 result statist signific
 dr nemeroff say page paper im read statist signific
differ guid care arm treatment usual regard mean number side effect week
proport patient experienc side effect differ
 dr bryan dechairo agre overal signific far higher respons remiss side effect
statist differ patient genet identifi medic
inappropri switch medic statist signific side effect
second question regard endpoint typic fda approv studi mention
studi present fda phase measur three endpoint outcom symptom improv
continu variabl impact patient number patient respond number patient
remit differ way measur use scale want get thought prozac
sens prozac geriatr studi present fda fail meet primari endpoint symptom improv
respons signific remiss fda approv use geriatr patient
base data submit fda thought data use prozac geriatr
popul last year
 dr nemeroff year
 dr bryan dechairo earli believ
 dr nemeroff ok dont believ would happen today your well awar number compani
recent year conduct clinic trial miss primari endpoint made secondari
endpoint approv fda fact origin rtm trial perform
know miss primari endpoint subsequ work order final get rtm approv
bring except would happen today
dr nemeroff task forc neg guidelin
statement offici guidelin posit
dr nemeroff view guidelin pharmacogenet test genesight
 dr nemeroff field conclud suffici scientif evid widespread use current
commerci avail pharmacogenom test area antidepress pharmacotherapi say
believ futur pharmacogenom tremend impact psychiatri believ
seen field oncolog particular somewhat lesser extent cardiovascular medicin
pharmacogenom extraordinarili import becom import part armamentarium
workgroup person discuss today opinion certainli entir
workgroup council research simpli think insuffici evid time recommend widespread
use pharmacogenom test area antidepress prescrib
 turn statement issu juli around guidelin know council research view
task forc offici decis would ever get chang final
guidelin come
 dr nemeroff question offici posit approv
board truste would love abl re-consid posit statement base new data would
love see new data would show signific place pharmacogenom help us decis
make treat depress patient
 safe assum studi
 dr nemeroff well clearli bravo myriad studi import studi
publish im glad publish
myriad et confer call rais final question call
around dr nemeroff statement et confer call dr dechairo
dismiss view offici statement puzzl
respons given dr nemeroff statement clear think worthwhil
listen last minut myriad confer call hear
myriad dismiss dr nemeroff commentari neg guidelin statement myriad et call
 mark address ceo capon referenc guidelin statement juli
afternoon public call head task forc novel biomark treatment said studi fail
neg guidelin statement stand without guidelin support make think your go get
broader reimburs coverag payor
 evp dr bryan dechairo bryan ill start clarifi public group head dr
nemeroff team ask sub-committe review pharmacogenom result
public review pharmacogenom guid studi actual publish sinc publish
today includ review differ guidelin last guidelin actual
issu treatment depress came updat sinc
current guidelin pharmacogenom treatment depress time
 follow question said guidelin statement endors board director
 evp dr bryan dechairo know happen within closed-door non-open minut
discuss privi say public statement public written statement around
guidelin updat sinc end treatment depress
dr nemeroff also believ fda statement mirror
apa statement appli genesight even referenc
dr nemeroff also believ fda novemb statement warn use
pharmacogenet test depress appli genesight specif dr nemeroff
note fda announc mirror apa statement group
actual thought may influenc fda ask statement could
appli consum test option dr nemeroff ad fda want say
would said consum test option dont believ
dr charl nemeroff comment fda novemb warn pharmacogenet test
 broadli lot nois field pharmacogenet last month big headlin
earli novemb fda issu statement warn pharmacogenet test curiou
made think peopl field respond statement
 dr nemeroff council research formal came statement vote may
meet council research meet final issu approv board
truste found quit remark fda issu almost ident statement thought might even
influenc fda pretti unusu phenomenon fda came warn specif relat
antidepress test even interest came clear warn
cours number consum test particularli come go
find antidepress test know algorithm
use color rel genesight certainli worri much patient get test complet
unrel use connect healthcar profession think fda warn shot across bow
data need collect order see place pharmacogenom test
obvious issu relat reimburs think much cost brca test breast
cancer cost benefit test pretti good indic risk breast ovarian cancer think
would agre evid use myriad test predict antidepress respons fall far short brca
test specif type cancer vulner
 know fda warn specif refer genesight reason think
warn appli genesight would refer new consum test option come
 dr nemeroff would realli fda want say would said consum
test option dont believ
later ceo capon disagre say genesight differenti consum
option part compani argument regulatori oversight ldt
genesight wherea fda oversight diagnost kit said
renew debat around ldt regul genesight prime
exampl fda want greater regulatori author diagnost
ceo mark capon view myriad call relat fda announc
obvious public commentari made privat discuss well think mention
happen bioutah togeth dr jeff shuren day actual came
dr shuren keynot speaker got chanc catch number topic
discuss year say alway publicli differenti consum test
ldt well know effort made year ago specif crack consum test
test done recreat basi without health-car profession involv alway
signific concern agenc think remain concern agenc -- area
concern -- impact patient could direct-to-consum type test obvious
differ space ldt space clear enforc discret remain ldt
space know clear distinct line think distinct remain
pleas see
guid accept
public set motion
rct catalyst come
new observ guid studi
addit previous publish view genesight clinic data
want highlight new thing learn guid studi
myriad fail primari endpoint four nine secondari endpoint outlin
public guid studi total studi addit
primari endpoint symptom improv base myriad releas sever
secondari endpoint guid studi base qids-
depress scale compani continu tout
respons remiss signific endpoint symptom improv
view view academ failur primari endpoint
depress scale render secondari endpoint irrelev
furthermor studi didnt achiev statist signific respect symptom
improv respons remiss across three depress scale
word symptom improv respons remiss
fail least one depress scale symptom improv fail
lastli signific improv percentag patient
side effect genesight-guid versu treatment-as-usu tau cohort
fact genesight guid arm modestli wors tau arm particularli
troubl given industri expert believ safeti area hold promis
pharmacogenom oppos predict clinic respons
note myriad didnt provid data per-protocol cohort
compani provid data intent-to-treat cohort includ patient
score mildli depress patient patient violat studi
protocol interestingli base data per-protocol cohort less
signific compar intent-to-treat cohort use data
might improv result
myriad publish ad-hoc analysi mean wasnt offici endpoint
compani look result patient went take incongru
medic baselin take congruent medic view analysi shed
light one inher problem limit genesight clinic util test
help subset popul believ problem
caus genesight miss primari endpoint studi genesight use determin
therapeut select patient treatment resist depress trd mean
patient gener alreadi medic test run evidenc studi
uncommon patient alreadi take appropri medic
repres green yellow genesight bucket genesight guid studi
roughli patient baselin start green therapi patient start
yellow therapi patient red therapi therapi
includ genesight test report therefor genesight result came back
test dramat chang decis make patient green
yellow bucket patient medic includ genesight test report
baselin unclear patient treat given physician wouldnt
know medic appropri baselin patient green medic
like recommend stay current medic patient yellow categori
like requir dose adjust given dynam wasnt major stratif
symptom improv genesight tau arm effect
dilut result patient start red bucket show
signific improv rel control group genesight test
abl interven chang decis make get patient correct therapi
summari clinic datagenesight-guidedtreatment-as-usu blind central rater week improv blind site rater week patient report week effect week patient side base per-protocol cohort base intent-to-treat cohort barclay
stratif patient baselin week
tau week eight
note exclud patient medic includ
genesight test report data present may
dynam demonstr chart patient place
green yellow therapi follow red therapi congruent show statist
signific improv week eight versu patient red therapi didnt
switch incongru set patient consist studi particip
cohort primarili consist patient genesight-guid arm patient
congruent arm statist signific result symptom improv
respons remiss compar
popul overal portion studi display valu genesight bring
patient take incorrect therapi red bucket said believ valu
partial dilut patient happen correct therapi
secondari endpoint respons remiss
public timelin cover manuscript inconsist myriad
public commentari given journal say origin receiv
first page guid studi say receiv journal psychiatr
test improv reduct patientscongruentincongru barclay
research revis accept
myriad confer call compani made note
switch journal public fact ceo capon state studi
latter stage review actual studi day review
journal psychiatr research myriad disclos switch journal
earn
ceo mark capon commentari genesight guid public timelin
 earn recent publish impact studi guid optum studi
later stage review three studi publish put us strong posit receiv addit
coverag decis fiscal note prepar remark rct call guid actual
offici name studi latter stage review obvious initi hope would
get acceler review public begin fiscal year think seen particularli
summer month larg number author typic review process realli acceler review
think tradit timelin point continu obvious encourag public
work quickli typic public process multipl round review respons
author complex think see typic timelin right encourag
focus get publish soon
 earn genesight anticip accept landmark guid public
end fiscal second quarter anticip public earlier delay
manuscript withdrawn submit second journal end review process first journal notifi
compani condit public proprietari genesight algorithm would need disclos sole base
upon desir protect intellectu properti manuscript withdrawn submit anoth journal
anticip accept second quarter second journal submit still high-qual
journal feel good journal select author made think perspect myriad
compani perspect realli requir get publish peer-review journal articl
realli tech assess committe interest need abl citat
evalu data merit peopl well capabl need get publish
peer-review journal cours work toward obvious expect last-minut
request first journal never certain might someth els request like
experi journal belief request journal would highli unlik
final studi author employ directli myriad includ
senior author anoth research consult affili
assurex specif author consult assurex greden unpaid receiv
research grant support assurex final author conduct clinic research
princip investig assurex author disclos affili
author affili guid studi
authoremploye myriad assurexconsult assurex healthresearch support assurex healthprincip investig assurex healthconsult myriad geneticsbryan dechairo senior authorxkryst brownxjam lixalexa gilbertxlindsey burnsxmichael jablonskixjohn gredenxsagar parikhxanthoni rothschildxxmichael thasexboadi dunlopxcharl debattistaxbr foresterxfr mondimorexrichard sheltonxmatthew macaluscoxcharl conwayaffili w/ myriad barclay
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
